Granulocyte-macrophage colony-stimulating factor (GM-CSF) but not granulocyte colony-stimulating factor (G-CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro

Clinical and Experimental Immunology

Volumn 120, Issue 2, 2000, Pages 392-398

  Hellmich, B ^a,c   Csernok, E ^a,d   Trabandt, A ^a   Gross, W L ^a   Ernst, M ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d Rheumaklinik Bad Bramstedt   (Germany)

Author keywords

Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; Polymorphonuclear neutrophils; Proteinase 3

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOPATHOGENESIS; MALE; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; VASCULITIS; WEGENER GRANULOMATOSIS;

ADULT; CELL MEMBRANE; CELLS, CULTURED; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; MALE; MIDDLE AGED; MYELOBLASTIN; NEUTROPHILS; PEROXIDASE; SERINE ENDOPEPTIDASES;

EID: 0034108492     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01205.x     Document Type: Article

References (43)

1. 1 Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88:1907-29.
2. 2 Spiekermann K, Rosler J, Emmendorfer A, Elsner J, Welte K. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia 1997; 11:466-78.
3. 3 Frampton JE, Lee CR, Faulds D. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994; 48:731-60.
4. 4 Anderlini P, Przepiorka D, Champlin R, Körbling M. Biological and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996; 88:2819-25.
5. 5 Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (first of two parts). N Engl J Med 1991; 327:28-35.
6. 6 Jain KK. Cutaneous vasculitis associated with granulocyte colony-stimulating factor. J Am Acad Dermatol 1994; 31:213-5.
7. 7 Johnson MM, Grimwood CR. Leukocyte colony stimulating factors. A review of associated dermatoses and vasculitides. Arch Dermatol 1994; 130:77-81.
8. 8 Hellmich B, Schnabel A, Gross WL. Treatment of severe neutropenia due to Felty's syndrome and systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum 1999; 29:82-99.
9. 9 Viddarson B, Geirsson AJ, Önundarson PT. Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome. Am J Med 1995; 98:589-91.
10. 10 Dreicer R, Schiller JH, Carbone PP, Mueller W, Odenwald E, Souza L, Riehm H. Granulocyte-macrophage colony stimulating factor and vasculitis (letter). Ann Intern Med 1989; 111:91-92.
11. 11 Merkel PA. Drugs associated with vasculitis. Curr Opin Rheumatol 1998; 10:45-50.
12. 12 Hoffmann GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-99.
13. 13 Schmitt WH, Gross WL. Vasculitis in the seriously ill patient: diagnostic approaches and therapeutic options in ANCA-associated vasculitis. Kidney Int 1998; 53 (S64):39-44.
14. 14 Hoffmann GS. Treatment of Wegener's granulomatosis: time to change the standard of care? Arthritis Rheum 1997; 40:2099-104.
15. 15 Guillevin L, Cordier J-F, Lohte F et al. A prospective, multicenter randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40:2187-98.
16. 16 Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32:45-53.
17. 17 Hellmich B, Schnabel A, Gross WL. Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis. Arthritis Rheum 1999; 42:1752-6.
18. 18 Snowden JA, Brooks PM. Hematopoetic stem cell transplantation in rheumatic diseases. Curr Opin Rheumatol 1999; 11:167-72.
19. 19 Gross WL, Schmitt WH, Csernok E. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol 1993; 91:1-2.
20. 20 Van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tools for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; i:425-9.
21. 21 Halbwachs-Mecarelli L, Bessou G, Lesavre P, Lopez S, Witko-Sarsat V. Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Letters 1995; 374:29-33.
22. 22 Keogan MT, Esnault VLM, Green AJ, Lockwood CM, Brown DL. Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 1992; 90:228.
23. 23 Csernok E, Ernst M, Schmitt WH, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95:244-50.
24. 24 Muller Kobold AC, Kallenberg CG, Tervaert JW. Leukocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis. Br J Rheumatol 1998; 37:901-7.
25. 25 Csernok E, Lüdemann J, Gross WL, Bainton DF. Ultrastructural localisation of proteinase 3, the target of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol 1990; 137:1113.
26. 26 Takatani H, Soda H, Fukuda M et al. Levels of recombinant human granulocyte colony stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrob Agents Chemother 1996; 40:988-91.
27. 27 Ernst M, Kern P, Flad H, Ulmer AJ. Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC). J Clin Imunol 1986; 6:170-81.
28. 28 Kallenberg CGM, Heeringa P, Tervaert JWC. Are antineutrophil cytoplasmic antibodies pathogenic in Wegener's granulomatosis? Lessons from in vitro and in vivo experimental findings. In: Shoenfeld Y, ed. The decade of autoimmunity. Amsterdam: Elsevier, 1999:227-34.
29. 29 Jenette CJ, Falk RJ. Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 1998; 13 (S1):16-20.
30. 30 Gross WL, Trabandt A, Csernok E. Pathogenesis of Wegener's granulomatosis. Ann Intern Med (Paris) 1998; 149:280-6.
31. 31 Csernok E, Szymkowiak CH, Mistry N, Daha MR, Gross WL, Kekow J. Transforming growth factor-beta (TGF-beta) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vascultitis. Clin Exp Immunol 1996; 105:104-11.
32. 32 Szymkowiak CH, Johnston TW, Csernok E, Gross WL. Expression of the human autoantigen of Wegener's granulomatosis (PR3) in a baculovirus expression system. Biochem Biophys Res Commun 1996; 219:283-9.
33. 33 Specks U, Fass DN, Fautsch MP, Hummel AM, Viss MA. Recombinant human proteinase 3, the Wegener's autoantigen, expressed in HMC-I cells is enzymatically active and recognized by c-ANCA. FEBS Letters 1996; 390:265-70.
34. 34 Jenne DE. Structure of the azurocidin, proteinase 3, and neutrophil elastase genes. Implications for inflammation and vasculitis. Am J Respir Crit Care Med 1994; 150:S147-54.
35. 35 Treweeke AT, Aziz KA, Zuzel M. The role of G-CSF in mature neutrophil function is not related to GM-CSF-type cell priming. J Leuk Biol 1994; 55:612-6.
36. 36 Balazovich KJ, Almeida HI, Boxer LA. Recombinant human G-CSF and GM-CSF prime human neutrophils for superoxide production through different signal transduction mechanisms. J Lab Clin Med 1991; 118:576-84.
37. 37 Kekow J, Szymkowiak CH, Gross WL. Involvement of cytokines in granuloma formation within primary systemic vasculitis. In: Romagnani S, ed. Cytokines: basic principles and clinical applications. New York: Raven Press, 1992:341-8.
38. 38 Leavey PJ, Sellins KS, Thurman G et al. In vivo treatment with granulocyte colony stimulating factor results in divergent effects on neutrophil functions measured in vitro. Blood 1998; 92:4366-74.
39. 39 Pollmächer T, Korth C, Mullington J et al. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 1996; 86:900-5.
40. 40 Hartung T, Döcke WD, Gantner F et al. Effect of granulocyte colony stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995; 85:2482-9.
41. 41 Kocher M, Edberg JC, Fleit HB, Kimberly RP. Antineutrophil cytoplasmic antibodies preferentially engage Fc gamma RIIIb on human neutrophils. J Immunol 1998; 161:6909-14.
42. 42 Ohsaka A, Saionjii K, Sato N et al. Granulocyte colony stimulating factor downregulates the surface expression of human leukocyte adhesion molecule 1 on human neutrophils in vitro and in vivo. Br J Haematol 1993; 84:574-80.
43. 43 Yong KL, Linch DC. Differential effects of granulocyte-and granulocyte-macrophage colony-stimulating factors (G-and GM-CSF) on neutrophil adhesion in vitro and in vivo. Eur J Haematol 1991; 49:251-9.